Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity

Inclusion Criteria: * Specific Inclusion criteria * For ovarian cancer patients: Histologically confirmed surgical diagnosis of high-grade serous (or undifferentiated) ovarian cancer * For CIN3 and cervical cancer patients: Histologically confirmed diagnosis of CIN3 or cervical cancer * For AML and CML patients: HLA-A2 positivity and diagnosis of AML or CML confirmed by bone marrow biopsy or peripheral blood * Shared inclusion criteria * No evidence of active progressive disease. For ovarian cancer patients, a woman with a rising CA125 and negative imaging is acceptable * Age ≥ 18 yrs and \< 70 yrs * ECOG 0-2 * Adequate hematologic assessment (results from the previous standard of care visit): * Absolute neutrophil count (ANC) greater than or equal to 1.0 x 109/L * Platelets greater than or equal to 100 x 109/L. * Written informed consent Exclusion Criteria: * Treatment with chemotherapy, radiation therapy, other immunotherapy or non-topical steroids within the past 3 weeks prior to initiation of the study. * Immunosuppressive therapy (excluding topical steroids) for any other condition. * Recurrent/progressive disease confirmed clinically, radiologically or histologically before entry into the study. (exclude versus inclusion criteria) * Persistent fever (\>24 hours) documented by repeated measurement or active uncontrolled infection in the last 4 weeks. * Active autoimmune disease, including, but not limited to, SLE, MS, ankylosing spondylitis.